Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
After Phase 3 results show major hair regrowth gains
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Subscribe To Our Newsletter & Stay Updated
